Definition and Overview
Exosomes are nano-sized (30-150 nm) extracellular vesicles (EVs) derived from multivesicular bodies (MVBs) within cells, released when MVBs fuse with the cell membrane [1]. Secreted by all cells, they contain proteins, miRNA, mRNA, DNA, and lipids, serving as important mediators of intercellular signaling [1].
Exosome therapy involves administering therapeutic exosomes to induce tissue regeneration, anti-inflammatory, and neuroprotective effects. Following research findings that much of stem cell therapeutic effects are mediated through secreted exosomes rather than the cells themselves, exosomes have gained attention as a "cell-free therapy" approach [4].
Exosome Composition and Biological Properties
Exosomes are vesicles surrounded by a phospholipid bilayer membrane containing hundreds to thousands of types of proteins (surface markers CD63, CD81, CD9), nucleic acids (miRNA, mRNA, ncRNA), and lipids [1].
Blood-brain barrier (BBB) crossing ability is a critical property of exosomes. Their small size and specialized surface molecules enable delivery to the central nervous system, showing potential for treating brain diseases that conventional drugs cannot reach [3].
Exosomes exhibit low immunogenicity, producing minimal immune responses even with allogeneic administration [4]. This eliminates the need for autologous cell harvesting, improving treatment accessibility.
MSC-Derived Exosomes
Exosomes secreted by mesenchymal stem cells (MSCs) are the most extensively studied therapeutic exosomes [4]. MSC-exosomes exhibit anti-inflammatory, immunomodulatory, neurotrophic, and angiogenic effects similar to their parent cells.
In myocardial protection studies, MSC-exosomes significantly reduced myocardial ischemia-reperfusion injury, with effects comparable to direct MSC transplantation [2].
In stroke models, intravenous MSC-exosome administration produced neural functional recovery, angiogenesis, and increased neuroplasticity [3]. These effects are related to miRNA such as miR-133b within exosomes regulating neural growth-related gene expression [3].
Neurological Applications Research
Phase 1 clinical trials of MSC-exosomes for post-stroke rehabilitation are underway. Preclinical data are accumulating for traumatic brain injury (TBI), spinal cord injury, ALS, and Parkinson's disease. Recovery promotion through neurotrophic factor delivery is being studied for peripheral nerve injury and autonomic dysfunction. Specialized exosomes (from IFN-gamma-stimulated dendritic cells) showing potential for myelin regeneration in multiple sclerosis have been reported [5].
Manufacturing and Standardization Challenges
Standardized manufacturing and quality control are key challenges for clinical translation of exosome therapy [1]. Properties vary by isolation method (ultracentrifugation, size exclusion chromatography, precipitation reagents), and source cell origin, culture conditions, and storage methods affect efficacy. MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines have been proposed for research standardization [1].
Comparison: Exosome vs Stem Cell Therapy
Advantages of exosome therapy include lower risks of pulmonary embolism, immune rejection, and tumorigenesis compared to cell transplantation; ease of cryopreservation and long-term storage; BBB crossing ability; and potential for standardized formulation development. Disadvantages include lack of manufacturing standardization, mass production costs, and insufficient clinical evidence.